Illumina, Inc. (NASDAQ:ILMN) Shares Acquired by John G Ullman & Associates Inc.

John G Ullman & Associates Inc. lifted its position in Illumina, Inc. (NASDAQ:ILMN) by 1.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,150 shares of the life sciences company’s stock after acquiring an additional 200 shares during the period. John G Ullman & Associates Inc.’s holdings in Illumina were worth $2,237,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Primecap Management Co. CA raised its holdings in Illumina by 3.6% in the 3rd quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock worth $328,158,000 after purchasing an additional 87,599 shares during the period. Intech Investment Management LLC boosted its stake in Illumina by 161.6% during the 3rd quarter. Intech Investment Management LLC now owns 7,845 shares of the life sciences company’s stock worth $1,023,000 after purchasing an additional 4,846 shares during the last quarter. Moors & Cabot Inc. grew its stake in Illumina by 1.7% during the 3rd quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company’s stock valued at $759,000 after acquiring an additional 95 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in Illumina by 1,073.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 125,126 shares of the life sciences company’s stock worth $16,318,000 after buying an additional 114,466 shares in the last quarter. Finally, NS Partners Ltd increased its position in Illumina by 2.5% during the third quarter. NS Partners Ltd now owns 37,103 shares of the life sciences company’s stock worth $4,839,000 after purchasing an additional 900 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ILMN. Stephens increased their target price on shares of Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. StockNews.com began coverage on shares of Illumina in a report on Thursday, August 29th. They issued a “buy” rating for the company. Barclays lifted their price objective on shares of Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. lifted their target price on shares of Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, UBS Group raised their target price on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Illumina has a consensus rating of “Moderate Buy” and a consensus price target of $164.00.

Illumina Trading Down 2.5 %

Shares of ILMN opened at $131.68 on Thursday. The firm’s fifty day simple moving average is $140.18 and its two-hundred day simple moving average is $124.52. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a 12 month low of $93.51 and a 12 month high of $156.66.

Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. During the same quarter last year, the firm earned $0.33 EPS. The company’s quarterly revenue was down 3.5% compared to the same quarter last year. Equities analysts expect that Illumina, Inc. will post 4.11 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.